

Sequence Listing. The disk copy of the Sequence Listing, file "4045-0109P.ST25.txt", is identical to the paper copy, except that it lacks formatting.

The amendments made to the specification are intended to add SEQ ID NOS. to the two nucleotide sequences on pages 5 and 30. No new matter is introduced by these amendments.

A marked up version of the changes made by this amendment is attached hereto.

The Office Action providing the Notice to Comply was accompanied by an "Attachment for PTO-948", providing information about how to effect drawing changes. The Attachment sets a time for complying with correction of informalities in drawings "within the time period set in the attached Office communication." However, the "attached Office communication" did not include any form PTO-948 indicating the need for any drawing corrections. Thus, Applicants presume that no drawing corrections are presently required. In a telephone conversation with the Examiner on September 28, the Examiner indicated that this attachment was irrelevant at present, as no form PTO-948 had yet been sent. The Examiner is requested to send a form PTO-948, indicating whether the present drawings are acceptable or must be corrected, with the first Office Action on the merits.

Docket No. 4045-0109P

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By Mark J. Nuell  
Mark J. Nuell, #36,623

DRN/BCF  
4045-0109P

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

Attachments:

Disk Copy of Sequence Listing  
Paper Copy of Sequence Listing  
Copy of Notice to Comply  
Version with markings to show changes made  
(Rev. 03/27/01)

VERSION WITH MARKINGS TO SHOW CHANGES MADE

(material being added is underlined)

**The paragraph beginning on page 5, line 18:**

Two aptamers have been shown to have thrombin binding properties. Aptamer d(GGTTGGTGTGGTTGG) (SEQ ID NO:1) (ODN 1a) is directed against thrombin exosite 1, the fibrinogen binding site (5). Aptamer d(AGTCCGTGGTAGGGCAGGTTGGGTGACT) (SEQ ID NO:2) (ODN 2a) is directed against exosite 2, the heparin binding site (29). Both ODN 1b and ODN 2b bind readily to free thrombin. Radioiodination of stannyl oligodeoxyribonucleotides has provided high specific activity [<sup>123</sup>I, <sup>125</sup>I] aptamers for this investigation (14).

**The paragraph beginning on page 30, line 1:**

TABLE 1: Oligodeoxynucleotide aptamers directed to human thrombin exosites 1(SEQ ID NO:1) and 2(SEQ ID NO:2) used in this work: a: X=Y=nil; b: X=IVDU, Y=nil; c: X=IVDU, Y=biotin; d: X=IVDU, Y=biotin-streptavidin; e: X=nil, Y=biotin; f: X=nil, Y=biotin-streptavidin.